ZYNE - Zynerba Pharmaceuticals Stock Price, News & Analysis

$14.59 0.42 (2.96 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$14.17
Today's Range$14.09 - $14.70
52-Week Range$5.42 - $25.95
Volume332,003 shs
Average Volume647,030 shs
Market Capitalization$197.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:ZYNE
  • CUSIP: N/A
  • Web: zynerba.com
Debt:
  • Current Ratio: 8.65%
  • Quick Ratio: 8.65%
Sales & Book Value:
  • Annual Sales: $10,000.00
  • Price / Sales: 19,769.45
  • Book Value: $4.77 per share
  • Price / Book: 3.06
Profitability:
  • Trailing EPS: ($2.59)
  • Net Income: $-23,380,000.00
  • Return on Equity: -50.64%
  • Return on Assets: -45.05%
Misc:
  • Employees: 12
  • Outstanding Shares: 13,550,000
 

Frequently Asked Questions for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by $0.05. During the same period last year, the business posted ($0.67) earnings per share. View Zynerba Pharmaceuticals' Earnings History.

Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?

9 analysts have issued 1-year price targets for Zynerba Pharmaceuticals' shares. Their forecasts range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' stock price to reach $15.13 in the next year. View Analyst Ratings for Zynerba Pharmaceuticals.

What are Wall Street analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (11/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
  • 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a increase in short interest during the month of October. As of October 13th, there was short interest totalling 2,836,313 shares, an increase of 27.4% from the September 29th total of 2,227,100 shares. Based on an average trading volume of 797,348 shares, the short-interest ratio is currently 3.6 days. Currently, 26.9% of the company's stock are sold short.

Who are some of Zynerba Pharmaceuticals' key competitors?

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the folowing people:

  • Armando Anido, Chairman of the Board, Chief Executive Officer (Age 59)
  • Terri B. Sebree, President (Age 59)
  • James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development (Age 53)
  • Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources (Age 60)
  • William Roberts, Vice President - Investor Relations and Corporate Communications
  • Ray Mannion, Vice President - Manufacturing
  • Brian Rosenberger, Vice President - Commercial (Age 48)
  • Warren D. Cooper M.D., Lead Independent Director (Age 64)
  • William J. Federici, Independent Director (Age 57)
  • Thomas L. Harrison, Independent Director (Age 69)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who owns Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include RTW Investments LP (1.51%), Granite Point Capital Management L.P. (1.51%), Perceptive Advisors LLC (0.99%), Wells Fargo & Company MN (0.26%), Engineers Gate Manager LP (0.24%) and Rothschild Investment Corp IL (0.21%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Who sold Zynerba Pharmaceuticals stock? Who is selling Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Who bought Zynerba Pharmaceuticals stock? Who is buying Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, RTW Investments LP, Granite Point Capital Management L.P., Wells Fargo & Company MN, Engineers Gate Manager LP, Cowen Inc. and Zeke Capital Advisors LLC. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy Zynerba Pharmaceuticals stock?

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $14.59.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $197.75 million and generates $10,000.00 in revenue each year. The company earns $-23,380,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Zynerba Pharmaceuticals employs 12 workers across the globe.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. Lancaster Avenue, Suite 300, DEVON, PA 19333, United States. The company can be reached via phone at +1-484-5817505 or via email at [email protected]


MarketBeat Community Rating for Zynerba Pharmaceuticals (ZYNE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Zynerba Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $15.13 (3.67% upside)

Consensus Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Price Target History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017Cantor FitzgeraldSet Price TargetBuy$17.00N/AView Rating Details
11/14/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
11/14/2017Piper Jaffray CompaniesBoost Price Target$16.00 -> $20.00N/AView Rating Details
10/1/2017Roth CapitalSet Price TargetBuy$15.00MediumView Rating Details
9/29/2017Canaccord GenuityBoost Price TargetBuy$9.00 -> $15.00HighView Rating Details
8/15/2017CIBCReiterated RatingOutperform -> Market PerformLowView Rating Details
8/15/2017HC WainwrightSet Price TargetHold$7.00LowView Rating Details
8/15/2017Jefferies Group LLCDowngradeBuy -> Hold$12.00 -> $7.00LowView Rating Details
8/14/2017Maxim GroupReiterated RatingHoldHighView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Earnings History by Quarter for Zynerba Pharmaceuticals (NASDAQ ZYNE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.59)($0.63)ViewN/AView Earnings Details
8/1/2017Q2 2017($0.60)($0.64)$0.38 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.55)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.53)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
2017 EPS Consensus Estimate: ($2.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.50)($0.56)
Q2 20173($0.62)($0.51)($0.57)
Q3 20173($0.64)($0.42)($0.56)
Q4 20173($0.66)($0.48)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zynerba Pharmaceuticals (NASDAQ ZYNE)

Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 23.59%
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ ZYNE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/23/2017Michael RappMajor ShareholderBuy25,745$9.94$255,905.30View SEC Filing  
10/19/2017Michael RappMajor ShareholderBuy44,255$9.59$424,405.45View SEC Filing  
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.00View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.00View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.00View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zynerba Pharmaceuticals (NASDAQ ZYNE)

Source:
DateHeadline
Cantor Fitzgerald Reiterates "$17.00" Price Target for Zynerba Pharmaceuticals, Inc. (ZYNE)Cantor Fitzgerald Reiterates "$17.00" Price Target for Zynerba Pharmaceuticals, Inc. (ZYNE)
www.americanbankingnews.com - November 21 at 8:15 PM
Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?Is It The Right Time To Buy Zynerba Pharmaceuticals Inc (ZYNE)?
finance.yahoo.com - November 20 at 9:32 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Hold Rating from Oppenheimer Holdings, Inc.Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Hold Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 19 at 10:20 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Downgraded by Zacks Investment Research to SellZynerba Pharmaceuticals, Inc. (ZYNE) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - November 18 at 9:44 AM
FY2017 EPS Estimates for Zynerba Pharmaceuticals, Inc. (ZYNE) Decreased by Oppenheimer HoldingsFY2017 EPS Estimates for Zynerba Pharmaceuticals, Inc. (ZYNE) Decreased by Oppenheimer Holdings
www.americanbankingnews.com - November 17 at 7:10 PM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights - GlobeNewswire (press release)
globenewswire.com - November 16 at 11:03 AM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational HighlightsZynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - November 16 at 11:03 AM
Zynerba reports 3Q lossZynerba reports 3Q loss
finance.yahoo.com - November 16 at 11:03 AM
Piper Jaffray Companies Boosts Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target to $20.00Piper Jaffray Companies Boosts Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target to $20.00
www.americanbankingnews.com - November 15 at 12:16 AM
Analyzing Zynerba Pharmaceuticals (ZYNE) & BeyondSpring (BYSI)Analyzing Zynerba Pharmaceuticals (ZYNE) & BeyondSpring (BYSI)
www.americanbankingnews.com - November 14 at 7:40 AM
Critical Analysis: Zynerba Pharmaceuticals (ZYNE) & OncoSec Medical (ONCS)Critical Analysis: Zynerba Pharmaceuticals (ZYNE) & OncoSec Medical (ONCS)
www.americanbankingnews.com - November 11 at 3:28 PM
Biotech M&A Momentum Attractive for Cannabinoid R&D SpaceBiotech M&A Momentum Attractive for Cannabinoid R&D Space
www.prnewswire.com - November 7 at 4:23 PM
Zynerba Pharmaceuticals to Present at Upcoming Investor ConferencesZynerba Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - November 7 at 4:23 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Recommendation of "Hold" by AnalystsZynerba Pharmaceuticals, Inc. (ZYNE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 1:42 PM
Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma ... - PR Newswire (press release)Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Neos Therapeutics, Zynerba Pharma ... - PR Newswire (press release)
www.prnewswire.com - October 30 at 8:53 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Sees Large Increase in Short InterestZynerba Pharmaceuticals, Inc. (ZYNE) Sees Large Increase in Short Interest
www.americanbankingnews.com - October 28 at 2:26 AM
How Biosynthesis is Revolutionizing Cannabinoid PharmaceuticalsHow Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals
www.marketwatch.com - October 24 at 12:56 PM
3 Marijuana Stocks That Like to Live Life Dangerously3 Marijuana Stocks That Like to Live Life Dangerously
finance.yahoo.com - October 24 at 12:56 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Michael Rapp Buys 25,745 SharesZynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Michael Rapp Buys 25,745 Shares
www.americanbankingnews.com - October 23 at 10:34 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Buys $424,405.45 in StockZynerba Pharmaceuticals, Inc. (ZYNE) Major Shareholder Buys $424,405.45 in Stock
www.americanbankingnews.com - October 23 at 10:34 PM
Critical Analysis: Zynerba Pharmaceuticals (ZYNE) and Alnylam Pharmaceuticals (ALNY)Critical Analysis: Zynerba Pharmaceuticals (ZYNE) and Alnylam Pharmaceuticals (ALNY)
www.americanbankingnews.com - October 22 at 10:10 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Rating Lowered to Hold at Zacks Investment ResearchZynerba Pharmaceuticals, Inc. (ZYNE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 18 at 8:58 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" at Zacks Investment ResearchZynerba Pharmaceuticals, Inc. (ZYNE) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - October 14 at 5:16 PM
Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last WeekLike a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
finance.yahoo.com - October 12 at 10:37 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Rating of "Hold" from AnalystsZynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 4:42 PM
Benzingas Top Upgrades, Downgrades For October 2, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For October 2, 2017 - Benzinga
www.benzinga.com - October 3 at 4:42 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital AnalystsZynerba Pharmaceuticals, Inc. (ZYNE) Given a $15.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - October 2 at 3:14 PM
5 Stocks To Watch For September 29, 2017 - Benzinga5 Stocks To Watch For September 29, 2017 - Benzinga
www.benzinga.com - October 1 at 6:44 AM
Zynerbas Recent Results Revitalize The Bull Case, But Risks RemainZynerba's Recent Results Revitalize The Bull Case, But Risks Remain
www.benzinga.com - September 30 at 10:52 AM
Zynerbas stock on a high as cannabis-based drug succeeds in trial - ReutersZynerba's stock on a high as cannabis-based drug succeeds in trial - Reuters
www.reuters.com - September 29 at 10:37 PM
Zynerba Pharmaceuticals Reaches Analyst Target PriceZynerba Pharmaceuticals Reaches Analyst Target Price
www.thestreet.com - September 29 at 5:35 PM
BRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C studyBRIEF-Zynerba Pharmaceuticals announces positive top line results in ZYN002 open label Phase 2 FAB-C study
www.reuters.com - September 29 at 5:35 PM
Zynerba Stock: Where Is It Headed From Here?Zynerba Stock: Where Is It Headed From Here?
www.investopedia.com - September 29 at 5:35 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Given "Hold" Rating at Oppenheimer Holdings, Inc.Zynerba Pharmaceuticals, Inc. (ZYNE) Given "Hold" Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 29 at 5:28 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Rating Reiterated by Cantor FitzgeraldZynerba Pharmaceuticals, Inc. (ZYNE) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - September 29 at 4:40 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Price Target Raised to $15.00 at Canaccord GenuityZynerba Pharmaceuticals, Inc. (ZYNE) Price Target Raised to $15.00 at Canaccord Genuity
www.americanbankingnews.com - September 29 at 10:56 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Raised to Overweight at Piper Jaffray CompaniesZynerba Pharmaceuticals, Inc. (ZYNE) Raised to Overweight at Piper Jaffray Companies
www.americanbankingnews.com - September 28 at 11:28 PM
Notable Thursday Option Activity: ZYNE, EPC, RDINotable Thursday Option Activity: ZYNE, EPC, RDI
www.thestreet.com - September 28 at 12:51 PM
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X SyndromeZynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome
globenewswire.com - September 28 at 12:51 PM
Zynerba Pharma Wins Big on Cannabis TrialZynerba Pharma Wins Big on Cannabis Trial
247wallst.com - September 28 at 12:51 PM
Zynerbas stock on a high as cannabis-based drug succeeds in trialZynerba's stock on a high as cannabis-based drug succeeds in trial
www.reuters.com - September 28 at 12:50 PM
Short Interest in Zynerba Pharmaceuticals, Inc. (ZYNE) Declines By 25.0%Short Interest in Zynerba Pharmaceuticals, Inc. (ZYNE) Declines By 25.0%
www.americanbankingnews.com - September 17 at 1:20 AM
Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Consensus Recommendation of "Hold" from BrokeragesZynerba Pharmaceuticals, Inc. (ZYNE) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 16 at 4:54 PM
Zynerba Pharmaceuticals (ZYNE) vs. Its Rivals Financial ContrastZynerba Pharmaceuticals (ZYNE) vs. Its Rivals Financial Contrast
www.americanbankingnews.com - September 14 at 2:22 AM
Zynerba Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire (press release)Zynerba Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 3:19 PM
Zynerba Pharmaceuticals to Participate in Upcoming Investor ConferencesZynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 6 at 3:19 PM
Nemus Bioscience CEO Talks Waves Of Dominance In The Cannabis Therapeutics Industry - BenzingaNemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry - Benzinga
www.benzinga.com - September 5 at 3:40 PM
2 Marijuana Stocks That Have Imploded Since August Began2 Marijuana Stocks That Have Imploded Since August Began
finance.yahoo.com - August 23 at 2:26 PM
Zynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Recommendation of "Hold" from BrokeragesZynerba Pharmaceuticals, Inc. (ZYNE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - August 22 at 4:36 PM
Canaccord Genuity Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $9.00 Price TargetCanaccord Genuity Analysts Give Zynerba Pharmaceuticals, Inc. (ZYNE) a $9.00 Price Target
www.americanbankingnews.com - August 18 at 3:14 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Zynerba Pharmaceuticals (NASDAQ ZYNE) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.